Clinical Roundup Merck to present long-term data of Gardasil 9 and Gardasil at the EUROGIN international multidisciplinary HPV Congress March 20, 2026Vol.52 No.11
Cancer Policy Merck & Co. drug for treating NSCLC awarded FDA priority voucher January 09, 2026Vol.52 No.1By Claire Marie Porter
Cancer Policy Trump cuts IVF drug deal with Merck in exchange for tariff exemption October 24, 2025Vol.51 No.39By Claire Marie Porter
Drugs & Targets FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1) March 21, 2025Vol.51 No.11
Clinical Roundup Phase III trial of subcutaneous pembrolizumab with berahyaluronidase alfa meets primary endpoints November 22, 2024Vol.50 No.44
Clinical Roundup Data from Gardasil 9 studies reinforce importance of gender-neutral HPV vaccination in adults November 15, 2024Vol.50 No.43
Regulatory News ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitorsVote may lead to rollback of some indications held by BMS and Merck October 04, 2024Vol.50 No.37By Jacquelyn Cobb
Clinical Roundup Adjuvant Keytruda prolongs DFS in high-risk bladder cancer September 20, 2024Vol.50 No.35
Clinical Roundup Adjuvant treatment with cancer vaccine + Keytruda shows continued improvement in RFS and DMFS in resected high-risk advanced melanoma September 20, 2024Vol.50 No.35
